Sign in
Not yet recruitingPhase 2

Testing if dexmedetomidine, a sedative drug, helps to protect the brain after sudden cardiac arrest outside a hospital

Key facts

Who runs it
Medical University Of Vienna
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
1 Nov 2026
Expected to end
1 Nov 2028
Type of study
Interventional
Record updated
9 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adult patients ≥18 years of age experiencing out-of-hospital cardiac arrest
  • Sustained circulation (defined as ROSC or successful eCPR flow lasting for at least 20 minutes) within 90 minutes of suspected collapse
  • Comatose (Glasgow Coma Scale <8) on admission or suspected in patients receiving sedatives
  • Start of the trial drug is possible within 2 hours of hospital admission
  • Subjected to temperature control
  • Combined no-flow and low-flow time of ≥10 minutes

Who cannot take part

  • Requirement of acute surgery at screening
  • Known limitations to intensive care therapy and “Do Not Resuscitate” or “Allow Natural Death” orders
  • Expected death within 72 hours or known medical condition limiting expected survival to < 3 months
  • Known allergies or intolerances against any of the substances used in the trial
  • Known diseases that may interfere with biomarkers indicative of neurologic injury (e.g., cancer, inflammation, acute bleeding, stroke or infection of the central nervous system) at the discretion of the investigator
  • Unwitnessed cardiac arrest unless the no-flow time can safely be assumed to be <10minutes
  • Pregnancy or breastfeeding
  • Advanced directive of patient to decline resuscitation, intensive care measures, or participation in a clinical trial according to the local legal requirements of participating trial sites
  • Known pre-arrest CPC of 3 or 4
  • Time to sustained circulation > 90 minutes
  • No-flow time >10 minutes
  • Unmanageable hemodynamic and respiratory instability albeit the use of vasopressors and/or mechanical circulatory support – at the discretion of the treating physicians

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the effects of dexmedetomidine in patients after out-of-hospital cardiac arrest in comparison to placebo, as measured by the ranked composite of death before 72h and of neuron-specific enolase (NSE) 72h after cardiac arrest

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
DEXmedetomidine to Improve Neurologic Injury of patients after out-of-hospital cardiac arrest – a phase II randomized, double blind, placebo-controlled, parallel group trial
Record updated
9 November 2026